{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:07:04Z","timestamp":1793383624411,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>To compare the efficacy and safety of different mechanical circulatory support (MCS) devices in CS. A total of 24 studies (7 randomized controlled trials\u2014RCTs\u2014and 17 non-RCTs) involving 11,117 patients were entered in a Bayesian network meta-analysis. The primary endpoint was 30-day mortality. Secondary endpoints were stroke and bleeding (requiring transfusion and\/or intracranial and\/or fatal). Compared with no MCS, extra-corporeal membrane oxygenation (ECMO) reduced 30-day mortality when used both alone (OR 0.37, 95% CrI 0.15\u20130.90) and together with the micro-axial pump Impella (OR 0.13, 95% CrI 0.02\u20130.80) or intra-aortic balloon pump (IABP) (OR 0.19, 95% CrI 0.05\u20130.63), although the relevant articles were affected by significant publication bias. Consistent results were obtained in a sensitivity analysis including only studies of CS due to myocardial infarction. After halving the weight of studies with a non-RCT design, only the benefit of ECMO\u2009+\u2009IABP on 30-day mortality was maintained (OR 0.22, 95% CI 0.057\u20130.76). The risk of bleeding was increased by TandemHeart (OR 13, 95% CrI 3.50\u201359), Impella (OR 5, 95% CrI 1.60\u201318), and IABP (OR 2.2, 95% CrI 1.10\u20134.4). No significant differences were found across MCS strategies regarding stroke. Although limited by important quality issues, the studies performed so far indicate that ECMO, especially if combined with Impella or IABP, reduces short-term mortality in CS. MCS increases the hazard of bleeding.<\/jats:p>","DOI":"10.1007\/s10741-021-10092-y","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T21:02:17Z","timestamp":1615064537000},"page":"927-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mechanical circulatory support in patients with cardiogenic shock not secondary to cardiotomy: a network meta-analysis"],"prefix":"10.1007","volume":"27","author":[{"given":"Stefano","family":"Benenati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Canale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Vergallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Della","family":"Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Canepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-7287","authenticated-orcid":false,"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"issue":"229","key":"10092_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ahj.2020.08.012","volume":"28","author":"MD Lauridsen","year":"2020","unstructured":"Lauridsen MD, R\u00f8rth R, Lindholm MG et al (2020) Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction\u2013related cardiogenic shock from 2005 to 2017: a nationwide cohort study. Am Heart J 28(229):127\u2013137","journal-title":"Am Heart J"},{"issue":"16","key":"10092_CR2","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","volume":"136","author":"S van Diepen","year":"2017","unstructured":"van Diepen S, Katz JN, Albert NM et al (2017) Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 136(16):e232\u2013e268","journal-title":"Circulation"},{"key":"10092_CR3","doi-asserted-by":"crossref","unstructured":"Hochman JS, Sleeper LA, Webb JG et al\u00a0(1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 341(9):625\u201334","DOI":"10.1056\/NEJM199908263410901"},{"issue":"1 Pt 1","key":"10092_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","volume":"138","author":"CM O\u2019Connor","year":"1999","unstructured":"O\u2019Connor CM, Gattis WA, Uretsky BF et al (1999) Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138(1 Pt 1):78\u201386","journal-title":"Am Heart J"},{"issue":"19","key":"10092_CR5","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jacc.2015.03.036","volume":"65","author":"CS Rihal","year":"2015","unstructured":"Rihal CS, Naidu SS, Givertz MM et al (2015) 2015 SCAI\/ACC\/HFSA\/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. J Am Coll Cardiol 65(19):e7\u2013e26","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10092_CR6","doi-asserted-by":"publisher","first-page":"e006930","DOI":"10.1161\/CIRCINTERVENTIONS.118.006930","volume":"11","author":"S Vallabhajosyula","year":"2018","unstructured":"Vallabhajosyula S, O\u2019Horo JC, Antharam P et al (2018) Concomitant intra-aortic balloon pump use in cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation: a systematic review and meta-analysis. Circ Cardiovasc Interv 11(9):e006930","journal-title":"Circ Cardiovasc Interv"},{"issue":"8","key":"10092_CR7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.amjcard.2018.07.011","volume":"122","author":"SA Rios","year":"2018","unstructured":"Rios SA, Bravo CA, Weinreich M et al (2018) Meta-analysis and trial sequential analysis comparing percutaneous ventricular assist devices versus intra-aortic balloon pump during high-risk percutaneous coronary intervention or cardiogenic shock. Am J Cardiol 122(8):1330\u20131338","journal-title":"Am J Cardiol"},{"issue":"11","key":"10092_CR8","doi-asserted-by":"publisher","first-page":"e006486","DOI":"10.1161\/CIRCHEARTFAILURE.119.006486","volume":"12","author":"AA Al-Fares","year":"2019","unstructured":"Al-Fares AA, Randhawa VK, Englesakis M et al (2019) Optimal strategy and timing of left ventricular venting during veno-arterial extracorporeal life support for adults in cardiogenic shock: a systematic review and meta-Analysis. Circ Heart Fail 12(11):e006486","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10092_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ejcts\/ezy304","volume":"55","author":"Y Li","year":"2019","unstructured":"Li Y, Yan S, Gao S et al (2019) Effect of an intra-aortic balloon pump with venoarterial extracorporeal membrane oxygenation on mortality of patients with cardiogenic shock: a systematic review and meta-analysis. Eur J Cardiothorac Surg 55(3):395\u2013404","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"10092_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/acs.2018.11.09","volume":"8","author":"AR Wilson-Smith","year":"2019","unstructured":"Wilson-Smith AR, Bogdanova Y, Roydhouse S et al (2019) Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: systematic review and meta-analysis. Ann Cardiothorac Surg 8(1):1\u20138","journal-title":"Ann Cardiothorac Surg"},{"issue":"6","key":"10092_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jacc.2018.10.085","volume":"73","author":"JJ Russo","year":"2019","unstructured":"Russo JJ, Aleksova N, Pitcher I et al (2019) Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol 73(6):654\u2013662","journal-title":"J Am Coll Cardiol"},{"key":"10092_CR12","doi-asserted-by":"crossref","unstructured":"Ouweneel DM, Eriksen E, Sjauw KD et al\u00a0(2017) Percutaneous mechanical circulatory support versus intra-aortic balloon pump\u00a0in cardiogenic shock after acute\u00a0myocardial infarction J Am Coll Cardiol  24;69(3):278\u2013287","DOI":"10.1016\/j.jacc.2016.10.022"},{"issue":"11","key":"10092_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"issue":"343","key":"10092_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"18","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 18(343):d5928","journal-title":"BMJ"},{"issue":"355","key":"10092_CR15","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"12","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 12(355):i4919","journal-title":"BMJ"},{"key":"10092_CR16","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG\u00a0(2003) Measuring inconsistency in meta-analyses. British Medical Journal 327(7414):557\u201360","DOI":"10.1136\/bmj.327.7414.557"},{"issue":"2","key":"10092_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/eb-2015-102088","volume":"18","author":"D Mavridis","year":"2015","unstructured":"Mavridis D, Giannatsi M, Cipriani A, Salanti G (2015) A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health 18(2):40\u201346","journal-title":"Evid Based Ment Health"},{"issue":"1","key":"10092_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","volume":"7","author":"G van Valkenhoef","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE, Welton NJ (2016) Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods 7(1):80\u201393","journal-title":"Res Synth Methods"},{"issue":"23","key":"10092_CR19","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/j.jacc.2015.10.017","volume":"66","author":"D Burkhoff","year":"2015","unstructured":"Burkhoff D, Sayer G, Doshi D, Uriel N (2015) Hemodynamics of mechanical circulatory support. J Am Coll Cardiol 66(23):2663\u20132674","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10092_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367","author":"H Thiele","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann FJ et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367(14):1287\u20131296","journal-title":"N Engl J Med"},{"issue":"3","key":"10092_CR21","doi-asserted-by":"publisher","first-page":"469.e1","DOI":"10.1016\/j.ahj.2006.05.031","volume":"152","author":"D Burkhoff","year":"2006","unstructured":"Burkhoff D, Cohen H, Brunckhorst C, O\u2019Neill WW (2006) A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 152(3):469.e1\u20138","journal-title":"Am Heart J"},{"issue":"19","key":"10092_CR22","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.jacc.2008.05.065","volume":"52","author":"M Seyfarth","year":"2008","unstructured":"Seyfarth M, Sibbing D, Bauer I et al (2008) A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52(19):1584\u20131588","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10092_CR23","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","volume":"61","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 61(4):e78\u2013e140","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10092_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A et al (2019) 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J 40(2):87\u2013165","journal-title":"Eur Heart J"},{"key":"10092_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ahj.2017.12.009","volume":"199","author":"K Bendjelid","year":"2018","unstructured":"Bendjelid K (2018) IABP and cardiogenic shock: a heartbreaking story. Am Heart J 199:178\u2013180","journal-title":"Am Heart J"},{"issue":"6","key":"10092_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.amjcard.2016.11.037","volume":"119","author":"MB Basir","year":"2017","unstructured":"Basir MB, Schreiber TL, Grines CL et al (2017) Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol 119(6):845\u2013851","journal-title":"Am J Cardiol"},{"issue":"32","key":"10092_CR27","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/eurheartj\/ehz363","volume":"40","author":"H Thiele","year":"2019","unstructured":"Thiele H, Ohman EM, De Waha-Thiele S, Zeymer U, Desch S (2019) Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J 40(32):2671\u20132683","journal-title":"Eur Heart J"},{"issue":"1","key":"10092_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/SHK.0000000000001611","volume":"55","author":"J Duan","year":"2021","unstructured":"Duan J, Shi Y, Luo G et al (2021) Short-term efficacy and safety of different mechanical hemodynamic support devices for cardiogenic shock or high-risk Pci: a network meta-analysis of thirty-seven trials. Shock 55(1):5\u201313. https:\/\/doi.org\/10.1097\/SHK.0000000000001611","journal-title":"Shock"},{"issue":"6","key":"10092_CR29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jacc.2018.11.038","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Zucker MJ, Bazan VM et al (2019) Venoarterial ECMO for adults: JACC Scientific Expert Panel. J Am Coll Cardiol 73(6):698\u2013716","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10092_CR30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jchf.2018.09.009","volume":"6","author":"B Schrage","year":"2018","unstructured":"Schrage B, Burkhoff D, R\u00fcbsamen N et al (2018) Unloading of the left ventricle during venoarterial extracorporeal membrane oxygenation therapy in cardiogenic shock. JACC Hear Fail 6(12):1035\u20131043","journal-title":"JACC Hear Fail"},{"issue":"3","key":"10092_CR31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.athoracsur.2016.12.049","volume":"104","author":"S Tepper","year":"2017","unstructured":"Tepper S, Masood MF, Baltazar Garcia M et al (2017) Left ventricular unloading by impella device versus surgical vent during extracorporeal life support. Ann Thorac Surg 104(3):861\u2013867","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10092_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ejhf.668","volume":"19","author":"F Pappalardo","year":"2017","unstructured":"Pappalardo F, Schulte C, Pieri M et al (2017) Concomitant implantation of Impella\u00ae on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 19(3):404\u2013412","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10092_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/2048872618799745","volume":"8","author":"P Schiller","year":"2019","unstructured":"Schiller P, Hellgren L, Vikholm P (2019) Survival after refractory cardiogenic shock is comparable in patients with Impella and veno-arterial extracorporeal membrane oxygenation when adjusted for SAVE score. Eur Hear J Acute Cardiovasc Care 8(4):329\u2013337","journal-title":"Eur Hear J Acute Cardiovasc Care"},{"key":"10092_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2019.04.019","volume":"214","author":"NJ Udesen","year":"2019","unstructured":"Udesen NJ, M\u00f8ller JE, Lindholm MG et al (2019) Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J 214:60\u201368","journal-title":"Am Heart J"},{"issue":"1","key":"10092_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13613-016-0196-7","volume":"6","author":"C Aubron","year":"2016","unstructured":"Aubron C, DePuydt J, Belon F et al (2016) Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. Ann Intensive Care 6(1):97","journal-title":"Ann Intensive Care"},{"issue":"2","key":"10092_CR36","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.athoracsur.2013.09.008","volume":"97","author":"R Cheng","year":"2014","unstructured":"Cheng R, Hachamovitch R, Kittleson M et al (2014) Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg 97(2):610\u2013616","journal-title":"Ann Thorac Surg"},{"issue":"19","key":"10092_CR37","first-page":"30806","volume":"S1553\u20138389","author":"M Monteagudo-Vela","year":"2019","unstructured":"Monteagudo-Vela M, Simon A, Riesgo Gil F et al (2019) Clinical indications of IMPELLA short-term mechanical circulatory support in a tertiary Centre. Cardiovasc Revascularization Med S1553\u20138389(19):30806\u201330811","journal-title":"Cardiovasc Revascularization Med"},{"issue":"5","key":"10092_CR38","doi-asserted-by":"publisher","first-page":"e004337","DOI":"10.1161\/CIRCINTERVENTIONS.116.004337","volume":"10","author":"A Mandawat","year":"2017","unstructured":"Mandawat A, Rao SV (2017) Percutaneous mechanical circulatory support devices in cardiogenic shock. Circ Cardiovasc Interv 10(5):e004337","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10092-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-021-10092-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10092-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T23:05:57Z","timestamp":1650668757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-021-10092-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10092"],"URL":"https:\/\/doi.org\/10.1007\/s10741-021-10092-y","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,6]]},"assertion":[{"value":"22 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Ameri reports personal fees from Novartis, personal fees from Astra Zeneca, personal fees from Vifor, personal fees from Daiichi-Sankyo, personal fees from Boehringer Ingelheim, personal fees from Janssen, personal fees from Merck Sharp & Dohme, and personal fees from GlaxoSmithKline, outside the submitted work; Dr. Porto reports grants and personal fees from AstraZeneca, personal fees from Daiichi Sankyo, personal fees from Terumo Corporation, personal fees from Biotronik, personal fees from Bayer, personal fees from Amgen, and personal fees and non-financial support from Abiomed, outside the submitted work; Dr. Canepa reports grants and personal fees from Pfizer, personal fees from Novartis, personal fees from Akcea Therapeutics, and personal fees from Sanofi Genzyme, outside the submitted work; Dr. Crimi reports personal fees from Philips healthcare, outside the submitted work; other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}